GlassScriptPhysician profile
Zane Saul
NPI 1023089513
$512,740.98
in general payments reported to CMS, 2019-2025
39 companies · $99K in 2025
The $99K reported for 2025 was more than what 99% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113K · 2020: $40K · 2021: $40K · 2022: $47K · 2023: $62K · 2024: $111K · 2025: $99K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $231K · Food and Beverage: $14K · Travel and Lodging: $14K · Consulting Fee: $13K · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $231,248.09 |
| Food and Beverage | $14,027.30 |
| Travel and Lodging | $13,513.92 |
| Consulting Fee | $13,495.00 |
| Education | $193.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $247,213.32 | 2019-2025 | Descovy, Biktarvy, Yeztugo |
| Viiv Healthcare Company | $143,714.31 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Pfizer INC. | $78,042.22 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $18,654.83 | 2019-2025 | Pifeltro, Dificid, Zerbaxa |
| Insmed, INC. | $12,904.12 | 2019-2025 | Arikayce, Brinsupri |
| Melinta Therapeutics, LLC | $3,231.95 | 2019-2024 | Kimyrsa, Vabomere, Orbactiv |
| Abbvie INC. | $1,461.26 | 2019-2025 | Vraylar, Dalvance, Qulipta |
| Janssen Biotech, INC. | $810.18 | 2019-2023 | Symtuza |
| Cumberland Pharmaceuticals, INC. | $794.19 | 2019-2025 | Vibativ |
| Theratechnologies INC. | $605.06 | 2019-2025 | Trogarzo, Egrifta |
| Emd Serono, INC. | $524.87 | 2019-2025 | Serostim |
| Lilly USA, LLC | $503.83 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $492.82 | 2020-2025 | Farxiga, Breztri |
| Otsuka America Pharmaceutical, INC. | $479.92 | 2019-2025 | Rexulti |
| Janssen Products, LP | $323.99 | 2019-2021 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $318.50 | 2020-2024 | Trintellix |
| Paratek Pharmaceuticals, INC. | $307.29 | 2019-2025 | Nuzyra |
| Amgen INC. | $246.58 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.44 | 2022-2025 | Jardiance |
| Exact Sciences Corporation | $230.81 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $218.32 | 2019-2020 | |
| Astellas Pharma US INC | $211.14 | 2019-2024 | Cresemba |
| Aimmune Therapeutics, INC. | $177.60 | 2025 | Zenpep, Vowst |
| Novo Nordisk INC | $146.09 | 2020-2024 | Ozempic, Rybelsus |
| Csl Behring | $136.97 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.89 | 2022-2024 | Xifaxan |
| Janssen Pharmaceuticals, INC | $107.69 | 2019-2023 | |
| Ferring Pharmaceuticals INC. | $106.12 | 2023-2025 | Rebyota |
| Cormedix INC. | $73.36 | 2025 | Defencath |
| Eisai INC. | $68.07 | 2020-2021 | |
| Shionogi INC | $53.05 | 2021-2025 | Fetroja |
| Nabriva Therapeutics, Plc | $51.30 | 2020-2021 | |
| Glaxosmithkline, LLC. | $43.11 | 2023 | Arexvy, Shingrix |
| Janssen Scientific Affairs, LLC | $28.90 | 2023 | Symtuza |
| Idorsia Pharmaceuticals US INC | $27.62 | 2022-2023 | Quviviq |
| Esperion Therapeutics, INC. | $22.18 | 2024 | Nexletol |
| Acerus Pharmaceuticals Corporation | $15.56 | 2022 | |
| Amarin Pharma, INC. | $14.12 | 2020 | |
| Aytu Biopharma, INC. | $13.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zane Saul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.